DIA-Based Proteomics Identifies IDH2 as a Targetable Regulator of Acquired Drug Resistance in Chronic Myeloid Leukemia

Abstract

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

IDH2 stabilizes HIF‐1α‐induced metabolic reprogramming and promotes chemoresistance in urothelial cancer

“…It also restored CDDP sensitivity to some degree by decreasing the NADPH/NADP ratio and increasing ROS generation. In addition, recent articles have confirmed that AGI6780 shows apparent cytotoxicity in AML, Epstein–Barr virus‐related head and neck squamous carcinoma, and chemoresistant chronic myeloid leukemia (Shi et al , 2020 ; Liu et al , 2022 ; Zeng et al , 2022 ). Collectively, these recent data suggest that WT IDH2 can become a “druggable” target and that it might be a feasible approach for the clinical treatment of chemo‐resistant UC.…”

“…Importantly, we showed that specific knockdown of WT IDH2 led to suppression of metabolic reprogramming (Fig EV5A–G ) and re‐sensitization of chemoresistant UC cells to chemotherapeutic agents, indicating that this molecule could be a potential therapeutic target. Indeed, pharmacological inhibition of IDH2 by using AGI6780 showed significant cytotoxic effects when combined with GEM in GR cells both in vitro and in vivo (Wang et al , 2013 ; Liu et al , 2022 ). It also restored CDDP sensitivity to some degree by decreasing the NADPH/NADP ratio and increasing ROS generation.…”

Transcriptome and single-cell transcriptomics reveal prognostic value and potential mechanism of anoikis in skin cutaneous melanoma

“…However, the existing literature on these drugs in melanoma treatment is limited, and our study suggests their potential efficacy in cutaneous melanoma therapy. And further investigation is required evaluate its effectiveness in melanoma [ 48 ].…”